Pieris Pharma (PIRS) Tops Q3 EPS by 1c

Pieris Pharma (NASDAQ: PIRS) reported Q3 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15).

Cash and cash equivalents totalled $36.6 million at September 30, 2016, compared to $29.3 million at December 31, 2015. The increase in cash was driven primarily by the $16.5 million gross private placement financing completed in June 2016.

For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• ResMed (RMD) Tops Q3 EPS by 20c
• Data I/o Corp (DAIO) Misses Q2 EPS by 7c